The global glycated albumin assay market is on a remarkable growth trajectory, driven by increasing healthcare demands and advancements in diabetes management. Valued at USD 223.9 million in 2024, the market is projected to surge to an impressive USD 504 million by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 8.4%.

The glycated albumin assay is a crucial tool in modern healthcare, enabling the precise quantification of glycated albumin in human serum. This test is particularly significant for diabetic patients, as it provides essential insights into glucose control over recent weeks—an important factor for effective diabetes management. The glycated albumin assay is increasingly recognized for its role in complementing the widely used HbA1c test, especially in cases where HbA1c results may not fully represent glycemic control.

With the prevalence of diabetes continuing to rise globally, the demand for reliable and accurate testing methods like the glycated albumin assay is expected to drive market growth. Healthcare providers and patients alike benefit from the nuanced understanding of glucose levels that this assay provides, enabling more precise and effective diabetes management.

As the market for glycated albumin assays expands, advancements in technology and increased awareness about the benefits of comprehensive glucose monitoring are likely to further propel growth. The projected rise to a market size of USD 504 million by 2034 underscores the critical role this assay will play in the future of diabetes care.

Key Takeaways from the Market Study:

●       The United States is estimated to register at a CAGR of 8.7% by 2034.

●       A 13.7% CAGR was recorded between 2019 and 2023 for Japan's market.

●       China is expected to achieve a CAGR of 9% from 2024 to 2034.

●       The type 2 diabetes segment is anticipated to expand at 8.1% CAGR by 2034.

●       Hospitals & diabetic care centers are expected to show a compound annual growth rate of 7.8% during the forecast period.

“As the healthcare sector grows and research and development investments become increasingly prevalent, they will drive demand for the glycated albumin assay market,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).

Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends! https://www.globenewswire.com/en/news-release/2024/03/11/2844010/0/en/Glycated-Albumin-Assay-Market-size-is-expected-to-reach-US-504-million-by-2034-Future-Market-Insights-Inc.html

Competitive Landscape:

Developing strategic partnerships can help enterprises expand output and satisfy consumer demand, which in turn increases revenue and market share. Promoting innovative products and technologies will make them profitable for users in the long run.

●       Hzymes Biotechnology Co., Ltd.: Hzymes Biotechnology, as the name implies, is most likely involved in the development of enzymes and biotechnological products. They may have experience developing assays for a variety of biomarkers, including glycated albumin.

●       Beijing Strong Biotechnologies, Inc- Beijing Strong Biotechnologies, situated in China, is most likely engaged in biotechnological research and development. They may be developing assays and diagnostic tools, such as those for assessing glycated albumin levels.

●       Diazyme Laboratories, Inc. (General Atomics)- Diazyme Laboratories specialises in the development and manufacturing of clinical diagnostic reagents. They may have diabetes tests and/or solutions for testing glycated albumin in clinical samples.

Key Companies Profiled:

• Asahi Kasei Pharma Corporation
• EKF Diagnostics Holdings plc
• Weldon Biotech India Private Limited
• Hzymes Biotechnology Co. Ltd.
• Beijing Strong Biotechnologies Inc.
• Diazyme Laboratories Inc. (General Atomics)
• Abbexa Limited
• Biomatik Corporation
• Abnova Corporation
• Geno Technology Inc.

Glycated Albumin Assay - Key Segments:

By Application:

• Type 2 Diabetes
• Type 1 Diabetes
• Prediabetes

By End User:

• Hospitals & Diabetic Care Centers
• Diagnostic Laboratories
• Others

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• South Asia and Pacific
• East Asia
• The Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube